Paediatric αβ haploidentical transplantation (Pαβlo)
This is a prospective phase II study of the safety and cost-effectiveness of paediatric patients receiving TCR α+β+/CD19+ cell depleted haploidentical donor stem cell transplantation compared to those receiving an alternate donor haematopoietic stem cell transplant.
- ·
Haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as GVHD prophylaxis
This phase II study will involve 6 transplant centres from Australia and New Zealand and is the ABMTRR's first prospective study. It is supported by a grant from the Arrow Bone Marrow Transplant Foundation, which enabled database enhancements to streamline data management for this and future registry studies.
- ·
Prophylactic early parenteral nutrition in BMT
This multicentre randomised controlled trial is an NHMRC funded study evaluating the effect of supplemental prophylactic early parenteral nutrition commenced prior to chemoradiotherapy compared to pragmatic standard nutrition care on disease free survival in patients about to commence conditioning chemoradiotherapy for allogeneic haematopoietic progenitor/stem cell transplantation. The ABMTRR will be providing long term outcome data for this study.
- ·
Non-relapse mortality in unrelated donor transplants
The number of unrelated donor transplants performed in Australia and New Zealand has increased markedly in the past 15 years. This retrospective analysis will examine the impact of changes in practice over this time, such as greater availability of fully matched donors, use of reduced intensity conditioning, graft vs host disease prophylaxis and supportive care.
- ·
The effect of genotype on transplant outcomes
This laboratory study is being done by Westmead Institute for Medical Research in conjunction with the ABMDR, analysing donor-recipient tissue samples. The ABMTRR is providing transplant outcome data so that the researchers can determine any effect of genotype on transplant outcome.
